Printer Friendly

MEIER NAMED PRESIDENT OF SANDOZ RESEARCH INSTITUTE

 MEIER NAMED PRESIDENT OF SANDOZ RESEARCH INSTITUTE
 EAST HANOVER, N.J., March 5 /PRNewswire/ -- Jurg Meier, Ph.D. has


been appointed president of the Sandoz Research Institute, Jacques F. Rejeange, president and chief executive officer of Sandoz Pharmaceuticals Corporation, announced today.
 Rejeange said that as president, Meier, who previously served as senior vice-president of preclinical research at the institute, will be responsible for overseeing all research and development work conducted in the United States for the pharmaceutical company's prescription and over-the-counter medications.
 A resident of Morristown, Meier received his doctorate in physical chemistry from the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his bachelor's degree in chemistry from the institute and was awarded a master's degree from Rensselaer Polytechnic Institute of Troy, N.Y.
 The author of more than 38 research papers, Meier began his career with Sandoz in 1971 as a research associate in the department of biopharmaceuticals at the company's world research headquarters in Basel, Switzerland. He has held increasing positions of responsibility including executive vice president of research and development for Biochemie, a Sandoz subsidiary in Austria.
 The Sandoz Research Institute is the drug discovery and development division of Sandoz Pharmaceuticals Corporation. Major areas of drug investigation include cholesterol control and atherosclerosis, central nervous system disorders, immunology, diabetes and cancer.
 -0- 3/5/92
 /CONTACT: David L. Winter of Sandoz Pharmaceuticals, 201-503-8600/ CO: Sandoz Research Institute; Sanoz Pharmaceuticals Corp. ST: New Jersey IN: MTC SU: PER


GK-OS -- NY035 -- 5413 03/05/92 11:38 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:251
Previous Article:LITIGATION IS COSTING THOUSANDS OF AMERICAN JOBS, KEENE CHAIRMAN TELLS FLORIDA ATLANTIC UNIVERSITY STUDENTS
Next Article:/A D V A N C E -- FOR RELEASE AT 7 P.M., EST, TODAY/ PRIME DISCOVERY AT AEA TECHNOLOGY'S HARWELL LABORATORY, UK
Topics:


Related Articles
GENSIA AND SANDOZ SIGN AGREEMENT FOR DIABETES RESEARCH
GENSIA AND SANDOZ SIGN AGREEMENT FOR DIABETES RESEARCH
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
MAGAININ PHARMACEUTICALS AND SANDOZ ANNOUNCE STRATEGIC ALLIANCE IN CANCER
SANDOZ ANNOUNCES $75M ALLIANCE WITH THE NEUROSCIENCES INSTITUTE, EXPANDS COMMITMENT TO CNS DISCOVERY
PROTEIN DESIGN LABS NAMES PHARMACEUTICAL EXECUTIVES TO HEAD CLINICAL DEPARTMENT
SANDOZ PHARMACEUTICALS CORPORATION AND CLINTRIALS RESEARCH INC. SIGN STRATEGIC ALLIANCE AGREEMENT
SYSTEMIX TO TAKE OVER SYSTEMIX/SANDOZ COLLABORATION ON HUMAN STEM CELL GROWTH FACTORS
SYSTEMIX AND SANDOZ TO FUND RESEARCH AT STANFORD UNIVERSITY
SANDOZ DONATES $1 MILLION TO GENE-MAPPING EFFORT AND FORMS RESEARCH CONSORTIUM WITH WHITEHEAD INSTITUTE AND STANFORD

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters